Qingdao NovelBeam Technology Co.,Ltd. (688677.SS) has a MoatMap StockRank of 45/100 based on Quality (73/100), Value (9/100), and Momentum (50/100) factor scores. The current signal is HOLD. Qingdao NovelBeam is a high-quality medical optics component manufacturer (Q: 72), but it lacks a strong macro tailwind from our 18-month themes to drive an asymmetric re-rating.
Qingdao NovelBeam Technology Co., Ltd. develops and manufactures high-end optical engines, medical endoscope systems, and precision optical components. The company is a critical global supplier of fluorescent endoscope optical modules, establishing a strong competitive moat through its advanced optical design and precision manufacturing capabilities. It operates as a key partner to leading multinational medical device corporations.
| Price | $16.75 |
| Market Cap | $2.7B |
| P/E (TTM) | 91.64 |
| P/E (Forward) | 71.83 |
| Price/Book | 11.33 |
| Return on Equity | 12.2% |
| Return on Invested Capital | 13.7% |
| Debt/Equity | 7.99 |
| Gross Margin | 64.2% |
| Operating Margin | 37.9% |
| Revenue Growth | 18.8% |
| Dividend Yield | 0.4% |
| Free Cash Flow | $2M |
Qingdao NovelBeam Technology Co.,Ltd. operates in the Medical Instruments & Supplies industry, part of the Healthcare sector (China).